Bairen Medical: Subsidiary's cross-linked collagen implant product approved for registration.

Bauren Medical announced that recently, the registration application of cross-linked collagen implant of its holding subsidiary, Albielur, has been approved by the National Medical Products Administration. This is the second product in the Albielur collagen series to be approved. The product is based on intact Type I collagen fibers, chemically cross-linked to improve structural stability and reduce immunogenicity, suitable for injection in the nasolabial fold area on the face. The sales of this product is subject to various factors and uncertainties, and the impact on the company's revenue cannot be predicted at the moment.